"There was also an emphasis on using pathways and navigation to help facilitate this large group of patients that are being seen by urologists," says Arpeet Shah, MD.
In this video, Arpeet Shah, MD, shares take-home points from the panel discussion "Good, Bad and Ugly of New BPH Treatments” that took place at the 2023 LUGPA Annual Meeting in Orlando, Florida. Shah is a urologist with Associated Urological Specialists in Homewood, Illinois.
We had a lively debate on a number of particular clinical cases regarding how we would treat [a patient's] BPH, but there were some take home points that we all agreed upon. One was the use of diagnostic testing when evaluating and managing [patients with] BPH. There's a real emphasis on finding objective measures of prostate and bladder health before determining the right treatment for patients with BPH; for example, using tests like UroCuff, cystoscopy, and transrectal ultrasound of the prostate to monitors patients and their need for medication therapy, or their need for escalation of therapy with different surgical procedures. There was also an emphasis on using pathways and navigation to help facilitate this large group of patients that are being seen by urologists. [Patients with] BPH usually comprise 40% of a practice. And so how do we see these patients in an efficient manner and a consistent manner so we're providing the greatest level of care consistently, whether they're seeing one provider or another in a practice? So using things like pathways, navigators, and advanced practice providers to help patients progress through a pathway was a very important point that was made.
This transcription was edited for clarity.